uniQure (NASDAQ:QURE) Receives $19.40 Average PT from Brokerages

Shares of uniQure (NASDAQ:QURE) have received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $19.40.

A number of equities analysts have commented on QURE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price target on shares of uniQure in a research note on Friday, September 20th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Tuesday, August 20th. The Goldman Sachs Group upped their price objective on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Finally, StockNews.com raised uniQure to a “sell” rating in a report on Monday, August 5th.

uniQure Trading Up 23.9 %

Shares of QURE stock opened at $5.65 on Tuesday. The company has a market capitalization of $274.30 million, a PE ratio of -0.91 and a beta of 0.95. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The business’s fifty day moving average is $6.09 and its 200 day moving average is $5.62. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.08. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $3.47 million. On average, equities research analysts anticipate that uniQure will post -4.04 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of the stock. Sectoral Asset Management Inc. bought a new stake in uniQure in the fourth quarter valued at approximately $1,981,000. Vestal Point Capital LP purchased a new stake in uniQure during the 4th quarter valued at $26,572,000. Pale Fire Capital SE grew its holdings in uniQure by 9.2% in the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after acquiring an additional 5,500 shares during the last quarter. Pennant Investors LP purchased a new position in shares of uniQure in the fourth quarter valued at about $328,000. Finally, Virtu Financial LLC bought a new position in shares of uniQure during the fourth quarter valued at about $195,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.